- Home
- » Tags
- » Mitoguazone
Top View
- United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
- Inhibitors of the Menin-Mll Interaction Inhibitoren Der Menin-Mll-Interaktion Inhibiteurs De L’Interaction Ménine-Mll
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- NEUPOGEN® (Filgrastim) Injection, for Subcutaneous Or Intravenous Use Prefilled Syringe Initial U.S
- Revisiting Intrathecal Therapy in Infants and Children Sharon Conroy, Martin Garnett, Michael Vloeberghs, Richard Grundy, Ian Craven, David Walker
- WO 2018/144869 Al 09 August 2018 (09.08.2018) W ! P O PCT
- Cbnå“Rresearch VOLUME 45»NUMBER 5-CNREA8-PP 1917-2404
- Customs Tariff - Schedule Xxi - 1
- Cisplatin, VP-16-213 and MGBG (Methylglyoxal Bis Guanylhydrazone) Combination Chemotherapy in Refractory Lymphoma, a Phase II Study
- WO 2012/136776 Al 11 October 2012 (11.10.2012) P O P C T
- Cytostatics in the Aquatic Environment: Analysis, Occurrence, and Possibilities for Removal
- The VIM3-Arac Regimen Followed by Autologous Stem Cell Transplantation in Refractory Or Relapsing Aggressive Non-Hodgkin’S Lymphoma
- Harmonized Tariff Schedule of the United States (2006) (Rev
- There Are No Bad Anticancer Agents, Only Bad Clinical Trial Designs-Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture1
- ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
- (12) United States Patent (10) Patent No.: US 8,962,275 B2 Liang Et Al
- 1 a Comprehensive Review of Economic Evaluations of Therapeutic Drug Monitoring Interventions for Cancer Treatments Dinusha T Vi
- Arylquinoline and Analog Compounds and Use Thereof to Treat Cancer David S